Search company, investor...

Laguna Pharmacueticals


Dead | Dead

Total Raised


About Laguna Pharmacueticals

Laguna Pharmaceuticals, formerly known as ChanRx, is a biopharmaceutical company advancing vanoxerine for treatment of atrial fibrillation and atrial flutter.

Headquarters Location

4225 Executive Square

Cleveland, Ohio, 44128,

United States


Missing: Laguna Pharmacueticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Laguna Pharmacueticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Laguna Pharmacueticals Patents

Laguna Pharmacueticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Cardiac arrhythmia, Piperazines, Stimulants, Dopamine reuptake inhibitors, Indoles


Application Date


Grant Date


Related Topics

Cardiac arrhythmia, Piperazines, Stimulants, Dopamine reuptake inhibitors, Indoles



Latest Laguna Pharmacueticals News

Rechristened Laguna Pharmaceuticals Raises $30M, Moves To San Diego

Feb 17, 2015

Laguna Pharmaceuticals, founded in 2006 as a spinout of Cleveland, OH-based drug discovery and testing company ChanTest, has raised $30 million in a Series B round of venture funding and relocated in San Diego. The company, previously known as ChanRx, also recruited former Amira Pharmaceuticals CEO Bob Baltera as CEO. Versant Ventures and Frazier Healthcare led the $30-million round, which was joined by existing investor Santé Ventures. The round is expected to fund a late-stage clinical trial of Laguna’s lone drug, a 1,4-dialkylpiperazine derivative (Vanoxerine). The drug is intended to treat atrial fibrillation, an irregular heartbeat estimated to currently affect about 2.3 million Americans. The company raised $5 million in 2011 from Santé Ventures and ChanTest founder and CEO Arthur “Buzz” Brown. ChanTest began in 1998 to provide testing services to help pharmaceutical and biotech companies assess cardiac risk early in the process of drug development. Boston’s Charles River Laboratories acquired ChanTest for $54 million at the end of October. While several drugs are currently available for treating heart arrhythmias, Laguna says current drug options are limited by poor efficacy and toxicity. In results from a mid-stage trial reported in late 2013 , the company said 76 percent of the patients given the highest oral dose (400 mg) of Vanoxerine converted to a normal heart rhythm within 8 hours, and 84 percent converted within 24 hours—a rate approaching that of the electrical shock treatment known as direct current cardioversion. In Baltera, Laguna gets a veteran CEO. The job at Laguna is his first CEO position since 2011, when he led the sale of Amira to Bristol-Myers Squibb (NYSE: [[ticker:BMY) for $325 million in cash, with an additional $150 million tied to meeting certain development milestones. At the time, Amira’s lead drug was a compound targeting pulmonary fibrosis, which Amira had advanced only through early stage clinical trials. Baltera successfully exempted two other drug candidates from the BMS deal, and a new company called Panmira Pharmaceuticals was established to advance development of those compounds. Baltera will be joining Laguna’s co-founder and chief medical officer, Howard Dittrich, who worked previously at NovaCardia and other cardiovascular companies. “This is about commercialization, it’s not about proof of concept,” Baltera told me in a recent phone interview. Laguna “is going to be a lean, mean, product development and commercialization machine.” Bruce V. Bigelow is the editor of Xconomy San Diego. You can e-mail him at or call (619) 669-8788 Follow @bvbigelow Share or Leave a Comment

Laguna Pharmacueticals Frequently Asked Questions (FAQ)

  • Where is Laguna Pharmacueticals's headquarters?

    Laguna Pharmacueticals's headquarters is located at 4225 Executive Square, Cleveland.

  • What is Laguna Pharmacueticals's latest funding round?

    Laguna Pharmacueticals's latest funding round is Dead.

  • How much did Laguna Pharmacueticals raise?

    Laguna Pharmacueticals raised a total of $36.23M.

  • Who are the investors of Laguna Pharmacueticals?

    Investors of Laguna Pharmacueticals include Sante, Frazier Healthcare Partners, Versant Ventures and BioMed Realty Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.